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Translational64Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer speciﬁc to the human urokinase-
type plasminogen activator receptor (uPAR). In preparation of using this tracer in humans, as a new promising
method to distinguish between indolent and aggressive cancers, we have performed PET studies in mice to
evaluate the in vivo biodistribution and estimate human dosimetry of 64Cu-DOTA-AE105.
Methods: Fivemice received iv tail injection of 64Cu-DOTA-AE105 andwere PET/CT scanned 1, 4.5 and22 hpost
injection. Volume-of-interest (VOI) were manually drawn on the following organs: heart, lung, liver, kidney,
spleen, intestine, muscle, bone and bladder. The activity concentrations in the mentioned organs [%ID/g] were
used for the dosimetry calculation. The %ID/g of each organ at 1, 4.5 and 22 hwas scaled to human value based
on a difference between organ and bodyweights. The scaled valueswere then exported toOLINDA software for
computation of the human absorbed doses. The residence times as well as effective dose equivalent for male
and female could be obtained for each organ. To validate this approach, of human projection usingmouse data,
ﬁve mice received iv tail injection of another 64Cu-DOTA peptide-based tracer, 64Cu-DOTA-TATE, and
underwent same procedure as just described. The human dosimetry estimates were then compared with
observed human dosimetry estimate recently found in a ﬁrst-in-man study using 64Cu-DOTA-TATE.
Results: Human estimates of 64Cu-DOTA-AE105 revealed the heart wall to receive the highest dose
(0.0918 mSv/MBq) followed by the liver (0.0815 mSv/MBq), All other organs/tissue were estimated to
receive doses in the range of 0.02–0.04 mSv/MBq. The mean effective whole-body dose of 64Cu-DOTA-AE105
was estimated to be 0.0317 mSv/MBq. Relatively good correlation between human predicted and observed
dosimetry estimates for 64Cu-DOTA-TATE was found. Importantly, the effective whole body dose was
predicted with very high precision (predicted value: 0.0252 mSv/Mbq, Observed value: 0.0315 mSv/MBq)
thus validating our approach for human dosimetry estimation.
Conclusion: Favorable dosimetry estimates together with previously reported uPAR PET data fully support
human testing of 64Cu-DOTA-AE105.Physiology, Nuclear Medicine
msvej 9 2100 – Copenhagen
-NC-ND license.© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The serine protease urokinase-type plasminogen activator (uPA)
and its receptor (uPAR) have been shown to be up-regulated during
cancer invasion and metastatic development [1–4]. By localized
proteolytic activity, causing degradation of the extracellular matrix,
uPAR facilitates cancer cells to escape the primary tumor and to be
transported by the vascular and/or lymphatic system to distal sites
where new metastatic lesions are established. In line with this,
multiple studies have, based on immunohistochemistry on biopsies
and blood-based ELISA, reported uPAR to be a strong prognosticmarker for poor prognosis and metastatic disease in a number of
cancers, including breast, prostate, colorectal, gastric and lung cancer
[3–11]. Thismakes uPAR a very interesting target for non-invasive PET
imaging, since this could enable a whole-body quantitative analysis of
uPAR expression in both the primary tumor and metastatic lesions
[12–14]. The development of a uPAR PET tracer could circumvent the
well-known limitations using random biopsies and/or blood samples
as an in-direct method for uPAR expression in the tumor tissue, and
hopefully provide improved diagnostic and prognostic information
for the individual patient.
Based on the small linear peptide AE105 with high afﬁnity for
uPAR, 64Cu-DOTA-AE105 is one of several promising uPAR PET
tracers recently developed in our group [15–19]. Before considering
translation into human use, estimates of human dosimetry are
important. To date, there have been only a limited number of
studies that have compared and validated mouse-derived predicted
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[20–25]. All these studies have used conventional biodistribution
analysis of dissected mouse tissue at different time points to
estimate human dosimetry. Despite the obvious differences in
anatomy and physiology between mice and man, relatively close
correlation between predicted vs. observed dosimetry have howev-
er been found, exempliﬁed by close predictions of 4 out of 6 PET
tracers in the study by Sakata and co-workers [22]. Moreover,
recently two studies have reported the use of PET image-derived
biodistribution analysis in mice for use to estimate human
dosimetry [26,27]. Importantly, a signiﬁcant correlation between
conventional biodistribution tissue analysis and image-derived
analysis were reported (p = 0.9666), thus validating this new
approach [27].
Therefore, in the present study we evaluated the in vivo
biodistribution of 64Cu-DOTA-AE105 in mouse organs using whole-
bodymicroPET/CT imaging. Residence timeswere estimated using the
radiation dose assessment resource (RADAR) models and were
extrapolated to humans based on simple assumptions on difference
between the species using the OLINDA dosimetry software. To verify
that human projection based on image-derivedmouse biodistribution
data from three time-points is a reasonable approach, we performed a
correlation analysis between projected human dosimetry based on
mouse data from whole body microPET/CT for the somatostatin
receptor-targeting PET tracer 64Cu-DOTA-TATE with data from a
recently human 64Cu-DOTA-TATE dosimetry PET study in our group
[28]. This article therefore present the ﬁrst human dose estimates for
64Cu-DOTA-AE105 based on mice studies and validates the approach
using 64Cu-DOTA-TATE as an example.2. Materials and methods
2.1. Tracer synthesis
64Cu was produced on a PETtrace cyclotron (GE Healthcare)
equipped with a beamline. The production of 64Cu was carried out via
the 64Ni(p,n)64Cu nuclear reaction using a solid target system
consisting of a water cooled target mounted on the beamline. The
target consisted of 64Ni metal (enriched to N99%) electroplated on a
silver disc backing. A proton beam of 16 MeV and a beam current of
20 μA were used. After irradiation, the target was transferred to the
laboratory for further chemical processing where 64Cu was isolatedFig. 1. Representative PET/CT images 1, 4.5 and 22 h post intravenous injection of 64Cu-DO
location of organs used for ROI analysis: 1) Heart/Blood, 2) Liver, 3) Kidney (not shown inusing ion exchange chromatography. Final evaporation from aqueous
HCl yielded 2–6 GBq 64Cu as 64CuCl2.
64Cu-DOTA-AE015 were synthesized by adding 64CuCl2
(≈150 MBq) to a vial containing 0.1 M ammonium acetate buffer
(pH = 8) and peptide (2 nmol), with a temperature of 70 °C. The
labeling of DOTA-AE105 took 60 min and resulted in greater than 95%
yield. No additional radiochemical puriﬁcation step was required. The
amount of unlabeled 64Cu in the product was less than 1%, as
demonstrated by radio-TLC. The speciﬁc activity was approximately
40 MBq/nmol.
DOTA-TATE was radiolabeled as recently described [28]. In brief,
DOTA-TATE was labeled with 64Cu by adding a sterile solution of
DOTA-TATE (0.3 mg) and gentisic acid (25 mg) in aqueous sodium
acetate (1 mL; 0.4 M, pH 5.0) to a dry vial containing 64CuCl2 (800–
1000 MBq) at ambient temperature for 10 min and diluted with 1 mL
water. Finally, the mixture was passed through a Millex-GP 0.22-mm
sterile ﬁlter (Millipore). The amount of unlabeled 64Cu in the product
was less than 1%, as demonstrated by radio-TLC. The speciﬁc activity
was approximately 5 MBq/mmol.2.2. Animal
A total of 10 mice (NMRI Nude, Taconic) were used in this study.
The animals were housed in 2 cages with 5 animals in each in a
climate-controlled room with 12:12-h light cycle. Animals had free
access to food and water during housing.2.3. MicroPET/CT
Five mice received tail vein injection of 64Cu-DOTA-AE105
(6 MBq) and ﬁve mice received 64Cu-DOTA-TATE (6 MBq). PET
scans were acquired with a microPET Focus 120 scanner (Siemens
Medical Solutions, Malvern, PA). The energy window of the emission
scans was set to 350–605 keV with a time resolution of 6 ns. The
acquired emission dataset was automatically stored in listmode. Each
mouse was PET/CT scanned 1, 4.5 and 22 h post injection: 10 min
static PET scan followed by a CT scan. CT data were acquired with a
MicroCAT II tomograph (Siemens Medical Solutions, Malvern, PA).
The x-ray tube with a 0.5-mm aluminum ﬁlter was set at a 80 kVp, a
tube current of 500 μA, and an exposure time of 700 ms per
projection. The voxel size was 0.095 × 0.095 × 0.095 m m3. During
the scanning, the animal was anesthetized using 2% isoﬂurane.TA-AE105 in the tail vein (6 MBq/0.24 μg peptide). Numbers in the picture indicates
this image), 4) Lung, 5) Intestine, 6) Muscle, 7) Bone, 8) Bladder.
Table 1
Mouse biodistribution of 64Cu-DOTA-AE105.
Source Organ 1 h 4.5 h 22 h
Blod 1.3 ± 0.5 1.5 ± 0.5 1.4 ± 0.6
Liver 12.3 ± 5.0 9.6 ± 4.6 6.2 ± 2.5
Kidney 3.9 ± 2.4 3.2 ± 1.3 2.9 ± 1.2
Lung 1.3 ± 0.4 1.7 ± 0.63 1.4 ± 0.3
Spleen 5.4 ± 2.0 3.3 ± 1.3 2.6 ± 0.8
Intestine 7.9 ± 2.8 8.6 ± 4.0 2.2 ± 0.7
Muscle 1.0 ± 0.7 0.9 ± 0.6 0.6 ± 02
Bone 0.9 ± 0.4 1.1 ± 0.4 1.1 ± 0.3
Bladder 62.0 ± 53.4 1.9 ± 1.3 0.7 ± 0.6
Table 3
Human residence times (Bq × hr/Bq administrated) estimates of 64Cu-DOTA-AE105
based on mouse residence times and modeled organ mass differences between the two
species.
Source Organ Female Male
Small intestine 3.00E-01 2.61E-01
Heart content 6.01E-01 5.99E-01
Kidneys 9.11E-02 7.65E-02
Liver 1.17E + 00 1.23E + 00
Lungs 1.24E-01 1.19E-01
Muscle 1.31E + 00 1.66E + 00
Bone 3.00E-01 2.57E-01
Spleen 4.94E-02 4.69E-02
Urinary bladder 3.35E-02 3.43E-02
Reminder body 1.37E + 01 1.34E + 01
Table 4
Predicted human dosimetry for 64Cu-DOTA-AE105 (mSv/MBq).
Source Organ Female Male
Adrenals 3.31E-02 2.59E-02
Brain 2.84E-02 2.27E-02
Breast 2.69E-02 2.11E-02
Gallbladder wall 3.45E-02 2.83E-02
Lower large intestine wall 3.24E-02 2.50E-02
Small intestine 6.07E-02 4.92E-02
Stomach wall 3.19E-02 2.52E-02
Upper large intestine wall 3.43E-02 2.69E-02
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All listmode data were postprocessed into 128 × 128 × 32
sinograms using a maximum a priori (3D-MAP) algorithms into
256 × 256 × 95 matrices with a voxel size of 0.43 mm3. The
resolution of the PET scanner was 1.5 mm at CFOV, and 1.8 mm at
38 mm off-centre using 3D-MAP. All results were analyzed using
Inveon software (Siemens Medical Solutions, Malvern, PA, USA) and
expressed as percent of injected dose per gram tissue (%ID/g). The
mouse organs were identiﬁed and 3D volumes of interest were
manually drawn on the CT images for all three time-points. The
following organs were included in the analysis: blood (heart), liver,
kidney, lung, spleen, intestine, muscle, bone and bladder.
2.5. Radiation dosimetry
The projected human doses were then computed for male and
females phantoms using OLINDA software (OLINDA/EXM by Vander-
bilt University, USA. Version: 1.1) with the human residence times as
input. The animal-human biokinetic extrapolation used in this study is
the percent kg/g method [29]. The radioactivity concentration in the
animal organ data was reported as percent of injected activity per
gram of tissue (%ID/g) before using in the below equation for the
extrapolation-to-humans:
%ID
organ
 
human
¼ %ID
g
 
animal
 kgTBweight
 
animal
 gorgan
kgTBweight
 
human
2
64
3
75
The animalwhole bodyweightwas 34 g (0.034 kg) and theweight
of the human organs were chosen from male (73 kg) and female
(58 kg) phantoms in OLINDA [30] which was used for the human
dosimetry calculation. The urinary elimination fraction was set at 75%
within 5 hours. The rest of the activity (25%) assumed to be retained in
the body and the removal of the remaining radioactivity can be
assumed by only radioactive decay. The extrapolated three point data
of the organs i.e. at 1, 4.5, 22 h were used to ﬁt the time activity curve
and determine the cumulated activity and residence times.Table 2
Mouse residence times (Bq × Hr/Bq administrated) of 64CuIDOTAIAE105 in mouse
organs.
Source Organ Mean
Small intestine 1.29E + 00
Heart content 3.83EI01
Kidneys 2.34EI02
Liver 3.85E + 00
Lungs 4.07EI02
Muscle 2.73E + 00
Bone 4.01EI01
Spleen 7.49EI02
Urinary bladder 1.24EI01
Remainder body 6.41E + 002.6. Human 64Cu-DOTA-TATE PET and dosimetry study
Observed human dosimetry data for correlation analysis were
taken from a recently published ﬁrst-in-man 64Cu-DOTA-TATE PET
study using data from 5 patients [28].
3. Results
Fig. 1 shows a representative whole-body mouse PET/CT images
used for ROI-based distribution analysis of 64Cu-DOTA-AE105 1, 4.5
and 22 h post injection. At 1 h p.i. the bladder and liver presented the
highest activity, followed by three organs with similar activity levels,
kidney, spleen and intestine. At 4.5 and 22 h, the liver was the organ
with highest activity, followed by the intestine. All other organs/tissue
had minimal activity levels 4.5 and 22 h p.i (Table 1). Calculated
residence-time of 64Cu-DOTA-AE105 derived from VOI analysis and
the corresponding human estimated residence times, are shown in
Tables 2 and 3, respectively.
The predicted human dosimetry for 64Cu-DOTA-AE105 is shown in
Table 4. The heart wall was projected to receive the highest dose in
both female and male, respectively (Female: 0.0918 mSv/MBq, Male:
0.0786 mSv/MBq) followed by the liver, osteogenic cells and the small
intestine. All other organs/tissue were estimated to receive doses in
the range of 0.02-0.04 mSv/MBq. The mean effective whole-bodyHeart wall 9.18E-02 7.86E-02
Kidneys 3.76E-02 2.97E-02
Liver 8.15E-02 6.38E-02
Lungs 2.32E-02 1.81E-02
Muscle 1.60E-02 1.28E-02
Overies 3.23E-02 2.56E-02
Pancreas 3.39E-02 2.68E-02
Red marrow 2.98E-02 2.41E-02
Osteogenic cells 7.59E-02 5.48E-02
Skin 2.43E-02 1.89E-02
Spleen 3.67E-02 2.88E-02
Testes 2.14E-02
Thymus 3.10E-02 2.41E-02
Thyroid 2.74E-02 2.21E-02
Urinary bladder wall 3.37E-02 2.93E-02
Uterus 3.19E-02
Total body 3.30E-02 2.58E-02
Effective dose 3.17E-02 2.51E-02
Table 5
Predicted and observed human dosimetry for 64Cu-DOTA-TATE (mSv/MBq).
Source organ Female
predicted
Male
predicted⁎
Male
Observed⁎⁎
Ratio
Adrenals 3.53E-02 2.75E-02 1.37E-01 4.98
Brain 3.36E-02 2.70E-02 1.27E-02 0.47
Breast 3.05E-02 2.40E-02 1.32E-02 0.55
Gallbladder wall 3.52E-02 2.89E-02 3.96E-02 1.37
Lower large intestine wall 3.70E-02 2.86E-02 4.32E-02 1.51
Small intestine 4.40E-02 3.74E-02 6.55E-02 1.75
Stomach wall 3.56E-02 2.83E-02 1.93E-02 0.68
Upper large intestine wall 3.71E-02 2.93E-02 2.18E-02 0.74
Heart wall 6.19E-02 5.10E-02 1.86E-02 0.36
Kidneys 2.08E-02 1.66E-02 1.39E-01 8.37
Liver 4.09E-02 3.19E-02 1.61E-01 5.05
Lungs 1.51E-02 1.19E-02 1.67E-02 1.40
Muscle 1.28E-02 1.04E-02 1.90E-02 1.83
Overies 3.61E-02
Pancreas 3.66E-02 2.91E-02 9.27E-02 3.19
Red marrow 2.96E-02 2.40E-02 2.65E-02 1.10
Osteogenic cells 7.64E-02 5.64E-02 3.35E-02 0.59
Skin 2.81E-02 2.20E-02 1.22E-02 0.55
Spleen 3.47E-02 2.74E-02 1.15E-01 4.20
Testes 2.51E-02 1.36E-02 0.54
Thymus 3.38E-02 2.60E-02 1.49E-02 0.57
Thyroid 3.17E-02 2.56E-02 1.41E-02 0.55
Urinary bladder wall 5.15E-02 4.35E-02 3.70E-02 0.85
Uterus 3.60E-02
Total body 3.41E-02 2.64E-02 2.50E-02 0.95
Effective dose 3.17E-02 2.52E-02 3.15E-02 1.25
⁎ Numbers used for correlation analysis in Fig. 2.
⁎⁎ Numbers reproduced from Ref. [28].
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MBq (male) corresponding to an effective dose of 6.34 mSv and
5.02 mSv, in female andmale respectively, after injection of 200 MBq
64Cu-DOTA-AE105 as planned in future clinical trial.Fig. 2. Comparison between predicted and observed dose estimates and total effective dose (
further details please see text. Black line indicates optimal ﬁt.To validate this approach, of human projections from mouse data,
a group of mice were injected with another 64Cu-DOTA peptide-based
PET ligand, the somatostatin receptor PET ligand 64Cu-DOTA-TATE,
followed by a similar VOI-based biodistribution analysis and identical
human dosimetry estimation method using OLINDA software. The
human dosimetry estimates from this analysis are shown in Table 5.
These mouse-derived dosimetry estimates were then correlated with
observed values from a recently published ﬁrst-in-man study, as
shown in Fig. 2. Some organs/tissue were predicted with very high
precision (muscle, lung, red marrow, urinary bladder wall) whereas
others were either over-estimated (osteogenic cells, heart wall) or
under-estimated (liver, kidney, adrenals, spleen, pancreas) when
comparing mouse-derived human dosimetry estimates and actual
observed human dosimetry data. Importantly, the effective whole
body dose was predicted with high precision (predicted value:
0.0252 mSv/Mbq, observed value: 0.0315 mSv/MBq) as shown in
Fig. 2, thus validating our approach for human dosimetry estimation
of 64Cu-DOTA-AE105.
4. Discussion
This study provides the ﬁrst human radiation dose estimates for
64Cu-DOTA-AE105. The heart-wall, liver, osteogenic cells and small
intestine are predicted to receive the highest absorbed dose. A total
effective whole-body dose of 0.0317 mSv/MBq (female) and
0.0251 mSv/MBq (male) is predicted, thus resulting in an effective
dose of 6.34 mSv and 5.02 mSv respectively, after injection of
200 MBq 64Cu-DOTA-AE105. This is similar to radiation dose from a
standard 18 F-FDG PET, where studies have found an absorbed dose
of approximately 0.019 mSv/MBq, equal to an effective dose of
6.65 mSv after injection of 350 MBq [31,32] and more than 7 times
below the 50 mSv dose limit used by the FDA for radiotracer
human-study protocols [33]. A predictive effective dose of
0.0251 mSv/MBq is moreover also in the same range as different
clinical used DOTA-conjugated peptides. 68Ga-DOTANOC, 68Ga-■) for 64Cu-DOTA-TATE in humans. Mouse data based on three different time points. For
294 M. Persson et al. / Nuclear Medicine and Biology 41 (2014) 290–295DOTATOC and 68Ga-DOTATATE have been found to have an
effective dose of 0.0167, 0.023 and 0.0257 mSv/MBq, respectively
in humans [34–36].
Accordingly, from a dosimetry point of view, a clinical use of
64Cu-DOTA-AE105 is feasible. Based on our validation data
analysis using 64Cu-DOTA-TATE as a model-compound, high
precision in the total effective dose estimate was observed
(predicted value: 0.025 mSv/MBq, observed value: 0.0315 mSv/
MBq), thus validating the overall approach of using biodistibution
data from image-derived three time-point nalysis, at least for 64Cu-
DOTA peptides. The ability to estimate single organ/tissue dosimetry,
our analysis revealed a less clear picture. A group of organs was
predicted with high precision such as muscle, lung and urinary
bladder wall. Other organs where either under-estimated (liver,
kidney) whereas others were over-estimated (osteogenic cells, heart
wall). Similar observations have been reported earlier using this
approach [22].
The discrepancy between mouse-derived dose estimates and
human observed doses, most widely reﬂects the difference in
metabolic rate between the two species. Furthermore, for an accurate
dosimetry calculation, an adequate number of data points (measure-
ments) and animal per time point should be used. Furthermore, the
timing of these points must be carefully selected, since these points
inﬂuence the conﬁdence in the ﬁt-to-data process for determining of
the residence times. In this study we have used 5 animals per tracer,
analyzed at three time-points. This are in agreement with other
studies were the number of animals per time point typically are
between 3–6, with the number of time points between 3 and 7
[20,21,26,27]. Despite the relatively low number of data points in this
study (1, 4.5 and 22 h) it seems that three data points are sufﬁcient
considering the relatively high concordance between predicted and
observed total body dosimetry values for 64Cu-DOTA-TATE (Fig. 2 +
Table 5). By analyzing the ratio (observed value divided by predicted
value), the total body estimate is only 5% from the observed value
(total body ratio: 0.95) and thus would not be signiﬁcantly different
from the predicted value. If this is a general phenomena or only valid
for 64Cu-DOTA-TATE, remains to be proven.
The high speciﬁc activity of our clinical batch protocol of 64Cu-
DOTA-AE105 only corresponds to a planned total injected dose of
1.5 μg (0.021 μg/kg body weight) compound when using 200 MBq
activity/dose. Mice have previously been dosed with AE105
analogues at 60 mg/kg, with no toxicity observed [37] thus resulting
in a safety margin of approximately 2.800.000 based on dose per
body weight when dosing at 200 MBq/1.5 μg. Moreover, our PET
studies in mice have also revealed no acute toxicity when
dosing 64Cu-DOTA-AE105 at 8 mg/kg. Finally, peptide-based PET
imaging using 64Cu-DOTA seem well tolerated since no toxicity
has been reported in more than 200 patients PET scanned with
64Cu-DOTA-TATE (unpublished data).
In conclusion, the favorable dosimetry estimates together with
previously reported uPAR PET data fully support future human testing
of 64Cu-DOTA-AE105.References
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